11 results on '"Acidosis drug therapy"'
Search Results
2. Effect of Sodium Bicarbonate on Systolic Blood Pressure in CKD: A Systematic Review and Meta-Analysis.
- Author
-
Beynon-Cobb B, Louca P, Hoorn EJ, Menni C, and Padmanabhan S
- Subjects
- Humans, Middle Aged, Blood Pressure, Sodium Bicarbonate therapeutic use, Antihypertensive Agents adverse effects, Kidney Failure, Chronic drug therapy, Acidosis drug therapy, Hypertension drug therapy
- Abstract
Background: Individuals with CKD are at a higher risk of cardiovascular morbidity and mortality. Acidosis is positively correlated with CKD progression and elevated systolic BP. Sodium bicarbonate is an efficacious treatment of acidosis, although this may also increase systolic BP. In this systematic review and meta-analysis, we summarize the evidence evaluating systolic BP and antihypertensive medication change (which may indicate systolic BP change) in response to sodium bicarbonate therapy in individuals with CKD., Methods: Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Cochrane Central Register of Controlled Trials, and World Health Organization (WHO) trials registry databases were searched for randomized control trials where sodium bicarbonate was compared with placebo/usual care in CKD stage G1-5 non-dialysis-dependent populations. Random effects meta-analyses were used to evaluate changes in systolic BP and BP-modifying drugs after sodium bicarbonate intervention., Results: Fourteen randomized control trials (2110 individuals, median follow-up 27 [interquartile range 97] weeks, mean age 60 [SD 10] years, mean systolic BP 136 [SD 17] mm Hg, mean eGFR 38 [SD 10] ml/min, mean serum bicarbonate 22 [SD 4] mmol/L) were eligible for inclusion. Meta-analysis suggested that sodium bicarbonate did not influence systolic BP in individuals with CKD stage G1-5. Results were consistent when stratifying by dose of sodium bicarbonate or duration of intervention. Similarly, there was no significant increase in the use of antihypertensive medication or diuretics in individuals taking sodium bicarbonate, whereas there was a greater decrease in antihypertensive medication use in individuals taking sodium bicarbonate compared with controls., Conclusions: Our results suggest, with moderate certainty, that sodium bicarbonate supplementation does not adversely affect systolic BP in CKD or negatively influence antihypertensive medication requirements., (Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of American Society of Nephrology.)
- Published
- 2023
- Full Text
- View/download PDF
3. Metabolic Acidosis and CKD Progression.
- Author
-
Madias NE
- Subjects
- Acidosis drug therapy, Acidosis etiology, Ammonium Compounds urine, Animals, Bicarbonates therapeutic use, Citric Acid urine, Disease Progression, Humans, Hydrogen-Ion Concentration, Renal Insufficiency, Chronic complications, Acidosis physiopathology, Bicarbonates blood, Renal Insufficiency, Chronic physiopathology
- Published
- 2021
- Full Text
- View/download PDF
4. Low Serum Bicarbonate and CKD Progression in Children.
- Author
-
Brown DD, Roem J, Ng DK, Reidy KJ, Kumar J, Abramowitz MK, Mak RH, Furth SL, Schwartz GJ, Warady BA, Kaskel FJ, and Melamed ML
- Subjects
- Acidosis drug therapy, Acidosis etiology, Adolescent, Bicarbonates therapeutic use, Buffers, Child, Child, Preschool, Disease Progression, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Kidney Glomerulus, Male, Proportional Hazards Models, Prospective Studies, Renal Insufficiency, Chronic etiology, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic therapy, Renal Replacement Therapy, Acidosis blood, Bicarbonates blood, Renal Insufficiency, Chronic blood
- Abstract
Background and Objectives: Studies of adults have demonstrated an association between metabolic acidosis, as measured by low serum bicarbonate levels, and CKD progression. We evaluated this relationship in children using data from the Chronic Kidney Disease in Children study., Design, Setting, Participants, & Measurements: The relationship between serum bicarbonate and a composite end point, defined as 50% decline in eGFR or KRT, was described using parametric and semiparametric survival methods. Analyses were stratified by underlying nonglomerular and glomerular diagnoses, and adjusted for demographic characteristics, eGFR, proteinuria, anemia, phosphate, hypertension, and alkali therapy., Results: Six hundred and three participants with nonglomerular disease contributed 2673 person-years of follow-up, and 255 with a glomerular diagnosis contributed 808 person-years of follow-up. At baseline, 39% (237 of 603) of participants with nonglomerular disease had a bicarbonate level of ≤22 meq/L and 36% (85 of 237) of those participants reported alkali therapy treatment. In participants with glomerular disease, 31% (79 of 255) had a bicarbonate of ≤22 meq/L, 18% (14 of 79) of those participants reported alkali therapy treatment. In adjusted longitudinal analyses, compared with participants with a bicarbonate level >22 meq/L, hazard ratios associated with a bicarbonate level of <18 meq/L and 19-22 meq/L were 1.28 [95% confidence interval (95% CI), 0.84 to 1.94] and 0.91 (95% CI, 0.65 to 1.26), respectively, in children with nonglomerular disease. In children with glomerular disease, adjusted hazard ratios associated with bicarbonate level ≤18 meq/L and bicarbonate 19-22 meq/L were 2.16 (95% CI, 1.05 to 4.44) and 1.74 (95% CI, 1.07 to 2.85), respectively. Resolution of low bicarbonate was associated with a lower risk of CKD progression compared with persistently low bicarbonate (≤22 meq/L)., Conclusions: In children with glomerular disease, low bicarbonate was linked to a higher risk of CKD progression. Resolution of low bicarbonate was associated with a lower risk of CKD progression. Fewer than one half of all children with low bicarbonate reported treatment with alkali therapy. Long-term studies of alkali therapy's effect in patients with pediatric CKD are needed., (Copyright © 2020 by the American Society of Nephrology.)
- Published
- 2020
- Full Text
- View/download PDF
5. Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over Study.
- Author
-
Kendrick J, Shah P, Andrews E, You Z, Nowak K, Pasch A, and Chonchol M
- Subjects
- Acidosis etiology, Cross-Over Studies, Female, Humans, Male, Middle Aged, Pilot Projects, Prospective Studies, Renal Insufficiency, Chronic complications, Acidosis drug therapy, Endothelium, Vascular drug effects, Sodium Bicarbonate pharmacology, Sodium Bicarbonate therapeutic use
- Abstract
Background and Objectives: We examined the effect of alkali replacement for metabolic acidosis on vascular endothelial function in patients with CKD., Methods: We performed a pilot, prospective, open-label 14-week crossover study examining the effect of oral sodium bicarbonate treatment on vascular function in 20 patients with an eGFR of 15-44 ml/min per 1.73 m
2 with low serum bicarbonate levels (16-21 mEq/L). Each period was 6 weeks in duration with a 2-week washout period in between. Patients were treated to goal serum bicarbonate of ≥23 mEq/L. The primary end point was change in brachial artery flow-mediated dilation (FMD) between treatment and control conditions. Secondary end points included changes in markers of inflammation, bone turnover, mineral metabolism, and calcification., Results: Eighteen patients completed the study and were included in the primary efficacy analysis. The mean (SD) age and eGFR were 59 (12) years and 26 (8) ml/min per 1.73 m2 , respectively. Serum bicarbonate increased significantly with sodium bicarbonate treatment (+2.7±2.9 mEq/L, P ≤0.001), whereas there was no change in bicarbonate levels in the control group. FMD significantly improved after sodium bicarbonate therapy (mean±SD, FMD baseline: 4.1%±4.1%; 6 weeks: 5.2%±2.9%; P =0.04) There was no significant change in FMD in the control group (mean±SD, FMD baseline: 4.6%±3.1%; 6 weeks: 4.1%±3.4%; P =0.20). Compared with control, sodium bicarbonate treatment resulted in a significant increase in FMD (mean, 1.8%; 95% confidence interval, 0.3 to 3.3; P =0.02). There was no significant change in bone markers or serum calcification propensity with treatment. Serum phosphorus and intact fibroblast growth factor 23 increased significantly during treatment., Conclusions: Treatment of metabolic acidosis with sodium bicarbonate significantly improved vascular endothelial function in patients with stages 3b and 4 CKD., (Copyright © 2018 by the American Society of Nephrology.)- Published
- 2018
- Full Text
- View/download PDF
6. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.
- Author
-
Bushinsky DA, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, Lee A, Parsell D, Mathur V, Li E, Buysse J, and Alpern R
- Subjects
- Acidosis diagnosis, Acidosis etiology, Acidosis physiopathology, Adult, Aged, Biomarkers, Bulgaria, Chelating Agents adverse effects, Double-Blind Method, Female, Georgia, Glomerular Filtration Rate, Humans, Kidney physiopathology, Male, Middle Aged, Polymers adverse effects, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic physiopathology, Time Factors, Treatment Outcome, United States, Acid-Base Equilibrium drug effects, Acidosis drug therapy, Bicarbonates blood, Chelating Agents therapeutic use, Polymers therapeutic use, Renal Insufficiency, Chronic complications
- Abstract
Background and Objectives: Metabolic acidosis is common in patients with CKD and has significant adverse effects on kidney, muscle, and bone. We tested the efficacy and safety of TRC101, a novel, sodium-free, nonabsorbed hydrochloric acid binder, to increase serum bicarbonate in patients with CKD and metabolic acidosis., Design, Setting, Participants, & Measurements: One hundred thirty-five patients were enrolled in this randomized, double-blind, placebo-controlled, multicenter, in-unit study (designated the TRCA-101 Study). Patients had a mean baseline eGFR of 35 ml/min per 1.73 m
2 , a mean baseline serum bicarbonate of 17.7 mEq/L, and comorbidities, including hypertension (93%), diabetes (70%), and heart failure (21%). Patients ate a controlled diet and were treated for 14 days with placebo or one of four TRC101 dosing regimens (1.5, 3, or 4.5 g twice daily or 6 g once daily). After treatment, patients were discharged and followed for 7-14 days., Results: All TRC101 treatment groups had a mean within-group increase in serum bicarbonate of ≥1.3 mEq/L ( P <0.001) within 72 hours of the first dose and a mean increase in serum bicarbonate of 3.2-3.9 mEq/L ( P <0.001) at the end of treatment compared with placebo, in which serum bicarbonate did not change. In the combined TRC101 treatment group, serum bicarbonate was normalized (22-29 mEq/L) at the end of treatment in 35% of patients and increased by ≥4 mEq/L in 39% of patients. After discontinuation of TRC101, serum bicarbonate decreased nearly to baseline levels within 2 weeks. All adverse events were mild or moderate, with gastrointestinal events most common. All patients completed the study., Conclusions: TRC101 safely and significantly increased the level of serum bicarbonate in patients with metabolic acidosis and CKD., (Copyright © 2018 by the American Society of Nephrology.)- Published
- 2018
- Full Text
- View/download PDF
7. Effects of oral sodium bicarbonate in patients with CKD.
- Author
-
Abramowitz MK, Melamed ML, Bauer C, Raff AC, and Hostetter TH
- Subjects
- Acidosis blood, Acidosis diagnosis, Acidosis physiopathology, Administration, Oral, Aged, Dose-Response Relationship, Drug, Female, Hand Strength, Humans, Logistic Models, Male, Middle Aged, Muscle, Skeletal drug effects, Muscle, Skeletal physiopathology, New York, Pilot Projects, Recovery of Function, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic physiopathology, Single-Blind Method, Sodium Bicarbonate adverse effects, Sodium Bicarbonate blood, Time Factors, Treatment Outcome, Acidosis drug therapy, Renal Insufficiency, Chronic drug therapy, Sodium Bicarbonate administration & dosage
- Abstract
Background and Objectives: Metabolic acidosis contributes to muscle breakdown in patients with CKD, but whether its treatment improves functional outcomes is unknown. The choice of dose and tolerability of high doses remain unclear. In CKD patients with mild acidosis, this study evaluated the dose-response relationship of alkali with serum bicarbonate, its side effect profile, and its effect on muscle strength., Design, Setting, Participants, & Measurements: In this single-blinded pilot study from March of 2009 to August of 2010, 20 adults with estimated GFR 15-45 ml/min per 1.73 m(2) and serum bicarbonate 20-24 mEq/L were treated during successive 2-week periods with placebo followed by escalating oral NaHCO3 doses (0.3, 0.6, and 1.0 mEq/kg per day). At each visit, handgrip strength and time required to complete 5 and 10 repetitions of a sit-to-stand test were measured., Results: Each 0.1 mEq/kg per day increase in dose produced a 0.33 mEq/L (95% confidence interval=0.23-0.43 mEq/L) higher serum bicarbonate. Sit-to-stand time improved after 6 weeks of oral NaHCO3 (23.8±1.4 versus 22.2±1.6 seconds for 10 repetitions, P=0.002), and urinary nitrogen excretion decreased (-0.70 g/g creatinine [95% confidence interval=-1.11 to -0.30] per 0.1 mEq/kg per day higher dose). No statistically significant change was seen in handgrip strength (29.5±9.6 versus 28.4±9.4 kg, P=0.12). Higher NaHCO3 doses were not associated with increased BP or greater edema., Conclusions: NaHCO3 supplementation produces a dose-dependent increase in serum bicarbonate and improves lower extremity muscle strength after a short-term intervention in CKD patients with mild acidosis. Long-term studies are needed to determine if this finding translates into improved functional status.
- Published
- 2013
- Full Text
- View/download PDF
8. The role of bicarbonate in CKD: evidence bulks up.
- Author
-
Simon EE and Hamm LL
- Subjects
- Female, Humans, Male, Acidosis drug therapy, Renal Insufficiency, Chronic drug therapy, Sodium Bicarbonate administration & dosage
- Published
- 2013
- Full Text
- View/download PDF
9. Treatment of acidosis in CKD.
- Author
-
Yaqoob MM
- Subjects
- Female, Humans, Male, Acidosis diet therapy, Acidosis drug therapy, Diet, Fruit, Hypertension complications, Renal Insufficiency, Chronic diet therapy, Renal Insufficiency, Chronic drug therapy, Sodium Bicarbonate therapeutic use, Vegetables
- Published
- 2013
- Full Text
- View/download PDF
10. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate.
- Author
-
Goraya N, Simoni J, Jo CH, and Wesson DE
- Subjects
- Acid-Base Equilibrium drug effects, Acidosis diagnosis, Acidosis etiology, Administration, Oral, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Antihypertensive Agents therapeutic use, Biomarkers blood, Biomarkers urine, Female, Glomerular Filtration Rate drug effects, Humans, Hypertension drug therapy, Kidney drug effects, Kidney physiopathology, Male, Middle Aged, Potassium blood, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic etiology, Sodium Bicarbonate administration & dosage, Sodium Bicarbonate adverse effects, Texas, Time Factors, Treatment Outcome, Acidosis diet therapy, Acidosis drug therapy, Diet adverse effects, Fruit, Hypertension complications, Renal Insufficiency, Chronic diet therapy, Renal Insufficiency, Chronic drug therapy, Sodium Bicarbonate therapeutic use, Vegetables
- Abstract
Background and Objectives: Current guidelines recommend Na(+)-based alkali for CKD with metabolic acidosis and plasma total CO2 (PTCO2) < 22 mM. Because diets in industrialized societies are typically acid-producing, we compared base-producing fruits and vegetables with oral NaHCO3 (HCO3) regarding the primary outcome of follow-up estimated GFR (eGFR) and secondary outcomes of improved metabolic acidosis and reduced urine indices of kidney injury., Design, Setting, Participants, & Measurements: Individuals with stage 4 (eGFR, 15-29 ml/min per 1.73 m(2)) CKD due to hypertensive nephropathy, had a PTCO2 level < 22 mM, and were receiving angiotensin-converting enzyme inhibition were randomly assigned to 1 year of daily oral NaHCO3 at 1.0 mEq/kg per day (n=35) or fruits and vegetables dosed to reduce dietary acid by half (n=36)., Results: Plasma cystatin C-calculated eGFR did not differ at baseline and 1 year between groups. One-year PTCO2 was higher than baseline in the HCO3 group (21.2±1.3 versus 19.5±1.5 mM; P<0.01) and the fruits and vegetables group (19.9±1.7 versus 19.3±1.9 mM; P<0.01), consistent with improved metabolic acidosis, and was higher in the HCO3 than the fruits and vegetable group (P<0.001). One-year urine indices of kidney injury were lower than baseline in both groups. Plasma [K(+)] did not increase in either group., Conclusions: One year of fruits and vegetables or NaHCO3 in individuals with stage 4 CKD yielded eGFR that was not different, was associated with higher-than-baseline PTCO2, and was associated with lower-than-baseline urine indices of kidney injury. The data indicate that fruits and vegetables improve metabolic acidosis and reduce kidney injury in stage 4 CKD without producing hyperkalemia.
- Published
- 2013
- Full Text
- View/download PDF
11. Correction of metabolic acidosis with potassium citrate in renal transplant patients and its effect on bone quality.
- Author
-
Starke A, Corsenca A, Kohler T, Knubben J, Kraenzlin M, Uebelhart D, Wüthrich RP, von Rechenberg B, Müller R, and Ambühl PM
- Subjects
- Absorptiometry, Photon, Acidosis blood, Acidosis diagnosis, Acidosis etiology, Adult, Bicarbonates blood, Biomarkers blood, Biopsy, Bone Density drug effects, Bone Remodeling drug effects, Bone and Bones diagnostic imaging, Bone and Bones metabolism, Bone and Bones pathology, Female, Femur Neck drug effects, Femur Neck metabolism, Humans, Ilium drug effects, Ilium metabolism, Lumbar Vertebrae drug effects, Lumbar Vertebrae metabolism, Male, Middle Aged, Switzerland, Time Factors, Treatment Outcome, X-Ray Microtomography, Acid-Base Equilibrium drug effects, Acidosis drug therapy, Bone and Bones drug effects, Kidney Transplantation adverse effects, Potassium Citrate therapeutic use
- Abstract
Background: Acidosis and transplantation are associated with increased risk of bone disturbances. This study aimed to assess bone morphology and metabolism in acidotic patients with a renal graft, and to ameliorate bone characteristics by restoration of acid/base homeostasis with potassium citrate., Methods: This was a 12-month controlled, randomized, interventional trial that included 30 renal transplant patients with metabolic acidosis (S-[HCO(3)(-)] <24 mmol/L) undergoing treatment with either potassium citrate to maintain S-[HCO(3)(-)] >24 mmol/L, or potassium chloride (control group). Iliac crest bone biopsies and dual-energy X-ray absorptiometry were performed at baseline and after 12 months of treatment. Bone biopsies were analyzed by in vitro micro-computed tomography and histomorphometry, including tetracycline double labeling. Serum biomarkers of bone turnover were measured at baseline and study end. Twenty-three healthy participants with normal kidney function comprised the reference group., Results: Administration of potassium citrate resulted in persisting normalization of S-[HCO(3)(-)] versus potassium chloride. At 12 months, bone surface, connectivity density, cortical thickness, and cortical porosity were better preserved with potassium citrate than with potassium chloride, respectively. Serological biomarkers and bone tetracycline labeling indicate higher bone turnover with potassium citrate versus potassium chloride. In contrast, no relevant changes in bone mineral density were detected by dual-energy X-ray absorptiometry., Conclusions: Treatment with potassium citrate in renal transplant patients is efficient and well tolerated for correction of metabolic acidosis and may be associated with improvement in bone quality. This study is limited by the heterogeneity of the investigated population with regard to age, sex, and transplant vintage.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.